利莫那班的药理学研究进展  

Progress of Pharmacological Studies on Rimonabant

作　　者：高行[1] 李盼[2] 邢树礼[1] 马凤君 樊彬[1] 贾琼 GAO Xing;LI Pan;XING Shuli;MA Fengjun;FAN Bin;JIA Qiong(Department of Pharmacy,Affiliated Hospital of Binzhou Medical College,Binzhou,Shandong Province,256600 China;Department of Outpatient Clinic,Affiliated Hospital of Binzhou Medical College,Binzhou,Shandong Province,256600 China)

机构地区：[1]滨州医学院附属医院药学部,山东滨州256600 [2]滨州医学院附属医院门诊部,山东滨州256600

出　　处：《系统医学》2022年第24期182-186,共5页Systems Medicine

摘　　要：在当前的全球范围中,肥胖已经成为一种流行性的疾病,而肥胖的发生则是由环境、遗传及后天等相关影响因素共同作用而导致。肥胖属于一种十分常见的慢性代谢性疾病,随着人们饮食及经济水平的不断提升,肥胖已经与酗酒、吸毒及艾滋病共同组成了全新的社会四大医学难题。人体的内源性类大麻素样物质与相关受体参与机体的能量平衡、脂肪代谢、糖类代谢、体质量控制;利莫那班是第一种大麻素Ⅰ型受体拮抗剂类减肥药物,其效果显著,可以通过内源性类大麻素系统发挥减肥效果。本研究对利莫那班的药理学做了一系列阐述,期望可以促进安全、高效的大麻素Ⅰ型受体拮抗剂的开发与使用。In the current global context,obesity has become an epidemic disease,and the causes of obesity are the interaction of environmental,genetic and acquired factors.Obesity is a very common chronic metabolic disease.With the continuous improvement of people's diet and economic level,obesity,together with alcoholism,drug abuse and AIDS,has formed four new social medical problems.The human body's endogenous cannabinoid like substances and related receptors participate in the body's energy balance,fat metabolism,carbohydrate metabolism,and weight control.Rimonabant is the first cannabinoid type I receptor antagonist type slimming drug,which has significant effect and can exert the slimming effect through the endogenous cannabinoid system.This study has made a series of explanations on the pharmacology of rimonabant,hoping to promote the development and use of safe and efficient cannabinoid type I receptor antagonists.

关 键 词：利莫那班 药理学 研究 进展 

分 类 号：R9[医药卫生—药学]